Cannabis use and transition to psychosis in people at ultra-high risk

L. R. Valmaggia[1,2]*†, **F. L. Day**[1,2]†, **C. Jones**[1,2], **S. Bissoli**[1,2], **C. Pugh**[1,2], **D. Hall**[1,2], **S. Bhattacharyya**[1,2], **O. Howes**[1,2], **J. Stone**[1,2], **P. Fusar-Poli**[1,2], **M. Byrne**[1,2] and **P. K. McGuire**[1,2]

[1] *Institute of Psychiatry, King's College London, London, UK*
[2] *Outreach and Support in South London (OASIS), South London and Maudsley NHS Trust, London, UK*

Background. Cannabis use is associated with an increased risk of developing a psychotic disorder but the temporal relationship between cannabis use and onset of illness is unclear. The objective of this study was to assess prospectively the influence of cannabis use on transition to psychosis in people at ultra-high risk (UHR) for the disorder.

Method. Lifetime and continued cannabis use was assessed in a consecutively ascertained sample of 182 people (104 male, 78 female) at UHR for psychosis. Individuals were then followed clinically for 2 years to determine their clinical outcomes.

Results. Lifetime cannabis use was reported by 134 individuals (73.6%). However, most of these individuals had stopped using cannabis before clinical presentation (n=98, 73.1%), usually because of adverse effects. Among lifetime users, frequent use, early-onset use and continued use after presentation were all associated with an increase in transition to psychosis. Transition to psychosis was highest among those who started using cannabis before the age of 15 years and went on to use frequently (frequent early-onset use: 25%; infrequent or late-onset use: 5%; χ_1^2=10.971, p=0.001). However, within the whole sample, cannabis users were no more likely to develop psychosis than those who had never used cannabis (cannabis use: 12.7%; no use: 18.8%; χ_1^2=1.061, p=0.303).

Conclusions. In people at UHR for psychosis, lifetime cannabis use was common but not related to outcome. Among cannabis users, frequent use, early-onset use and continued use after clinical presentation were associated with transition to psychosis.

Introduction

Cannabis is the most widely used illicit substance (United Nations Office on Drugs and Crime, 2013). Cannabis use can induce transient psychotic symptoms in healthy people (Bhattacharyya *et al.* 2012*b*) and exacerbate pre-existing psychotic symptoms in people with schizophrenia (e.g. Grech *et al.* 2005). Longitudinal studies in the general population indicate that cannabis use in adolescence or young adulthood is associated with the later development of psychotic-like symptoms and psychosis (Casadio *et al.* 2011) and it has been estimated that cannabis use is associated with a 40% increased risk of subsequently developing psychosis (Moore *et al.* 2007). However, whether the association between cannabis and

psychosis is causal remains unconfirmed. Psychosis vulnerability might predispose people to cannabis use; indeed, it has been suggested that people use cannabis in an effort to cope with psychotic symptoms ('self-medication'; Hall & Degenhardt, 2000). Cannabis use could also be a proxy marker for other psychosis risk factors, such as social isolation, psychosocial stress or trauma (Macleod *et al.* 2004; Gage *et al.* 2013).

The effect of cannabis use on psychosis risk appears to be modulated by several factors: the age at first use, the pattern of use, existing psychosis vulnerability, and genotype (Casadio *et al.* 2011). Epidemiological studies have found that initiation of cannabis use during adolescence is associated with an increased risk of developing psychosis (Arseneault *et al.* 2002; Konings *et al.* 2008), while studies of people with established psychosis indicate that early cannabis use is related to earlier onset (Stefanis *et al.* 2013; Tosato *et al.* 2013). A dose–response relationship between the pattern of use and psychotic symptoms or psychosis has also been reported, with heavier use increasing

the risk (van Os *et al.* 2002; Di Forti *et al.* 2009). Continued use after the onset of psychosis is linked to poorer outcomes (Gonzalez-Pinto *et al.* 2011; Stone *et al.* 2014). Several studies have found that cannabis is more likely to be associated with psychosis-like experiences in people who have an existing predisposition, on account of having subclinical psychotic experiences (van Os *et al.* 2002; Henquet *et al.* 2005) or a family history of psychosis (Miller *et al.* 2001; Stowkowy & Addington, 2013). There is also increasing evidence for a gene–environment interaction, with the likelihood of people who have used cannabis having psychosis or psychotic-like experiences being influenced by variation in genes such as catechol-*O*-methyltransferase (COMT) and protein kinase B (AKT1) (Caspi *et al.* 2005; van Winkel *et al.* 2011; Di Forti *et al.* 2012).

People at ultra-high risk (UHR) for psychosis are an ideal clinical group in which to investigate the putative role of cannabis use in the onset of psychosis, as 20–35% will develop the disorder within a few years following clinical presentation (Yung *et al.* 1998; Fusar-Poli *et al.* 2012). To date, studies of substance use in this population have reported inconsistent findings and few have investigated cannabis specifically in relation to psychosis onset (Addington *et al.* 2013). Phillips *et al.* (2002) and Auther *et al.* (2012) investigated cannabis use in large samples of people at high risk (*n*=100 and *n*=101, respectively) but did not find a significant difference in transition to psychosis between cannabis users and non-users. However, in a smaller sample (*n*=48), Kristensen & Cadenhead (2007) found that UHR participants who met diagnostic criteria for cannabis abuse or dependence were more likely to develop psychosis than those who had never used or used only minimally. These inconsistencies highlight the need for further work in UHR samples in order to understand the role of cannabis use in the onset of psychosis (van der Meer *et al.* 2012).

Our first aim in this study was to determine the relationship between cannabis use and transition to psychosis in a large sample of people who were identified as UHR and then followed clinically for 2 years. Our second aim was to establish whether the putative effect of cannabis use was influenced by the age at first use, the pattern of use and genetic vulnerability for psychosis. Our primary hypothesis was that cannabis use in people who were already at UHR would be associated with transition to psychosis. Our secondary hypotheses were that this effect would be particularly evident in participants who were frequent cannabis users, had started at an early age, continued using cannabis during the UHR phase, or had a family history of psychosis.

Method

Participants

Participants (*n*=182) were individuals who met the Personal Assessment and Crisis Evaluation (PACE) UHR criteria (Yung *et al.* 1998), through Outreach and Support in South London (OASIS), a clinical service for people at UHR for psychosis (Fusar-Poli *et al.* 2012). OASIS offers treatment to individual who meet one or more of the following: (i) attenuated positive psychotic symptoms; (ii) a brief psychotic episode lasting less than 1 week that resolved without antipsychotic medication (brief limited intermittent psychosis); and/or (iii) trait vulnerability (defined as the individual having either schizotypal personality disorder or a first-degree relative with a psychotic disorder) coupled with a recent decline in function. Use of substances is not considered an exclusion criterion. Demographic and clinical characteristics of the participants are presented in Table 1.

Baseline assessment of substance use

A modified version of the Cannabis Experience Questionnaire (Barkus *et al.* 2006), administered as an interview, was used to obtain information on lifetime use of cannabis, stimulants [e.g. amphetamine, ecstasy and 3,4-methylendioxymethamphetamine (MDMA)], cocaine, hallucinogens [e.g. lysergic acid diethylamide (LSD), mushrooms], inhalants (e.g. poppers, solvents), crack, opioids (e.g. heroin, morphine) and sedatives (e.g. Valium, sleeping pills). When use of a substance was reported, participants were asked in detail about current use, age of first (and last) use, and the frequency and duration of use for that substance. Participants were defined as being current users of a substance if they identified as such or if they reported any use in the preceding month. For each substance, the frequency (using Phillips *et al.* 2002) and duration (using Di Forti *et al.* 2009) of use data were recoded into dichotomous variables to allow sufficient power for statistical comparisons. Phillips *et al.* (2002) defined frequent use as once per week or more and infrequent use as less than once per week. Di Forti *et al.* (2009) defined long-term use as 5 years or more and short-term use as less than 5 years. Early-onset cannabis use was defined as use beginning before the age of 15 years (Arseneault *et al.* 2002). Lifetime users of cannabis were asked additional questions about unpleasant experiences associated with cannabis use. Past users of cannabis were asked an open-ended question about why they had chosen to stop their use ('If you are no longer using cannabis, why did you stop?'). A further assessment of substance use was performed in order to determine rates of continued use

Table 1. *Demographic and clinical characteristics of the total sample and comparison of the complete and incomplete/missing subsamples*

	Baseline substance use assessment				Follow-up substance use assessment		
	Total (n=182)	Complete (n=141)	Incomplete (n=41)	Test statistic	Complete (n=140)	Missing (n=42)	Test statistic
Mean age, years (S.D.)	22.9 (4.5)	22.7 (4.4)	23.8 (4.9)	$t_{180}=1.312$ $p=0.191$	22.7 (4.6)	23.8 (4.2)	$t_{180}=1.218$ $p=0.225$
Gender, n (%)							
Male	104 (57.1)	78 (55.3)	26 (63.4)	$\chi^2_1=0.850$	76 (54.3)	28 (66.7)	$\chi^2_1=2.022$
Female	78 (42.9)	63 (44.6)	15 (36.6)	$p=0.357$	64 (45.7)	14 (33.3)	$p=0.155$
Ethnicity, n (%)							
White	99 (54.4)	74 (52.5)	25 (60.9)	$\chi^2_2=1.717$	81 (57.9)	18 (42.8)	$\chi^2_2=3.295$
Black	55 (30.2)	46 (32.6)	9 (21.9)	$p=0.424$	38 (27.1)	17 (40.5)	$p=0.193$
Other	28 (15.4)	21 (14.9)	7 (17.1)		21 (15)	7 (16.7)	
Occupation, n (%)							
Unemployed	76 (41.8)	59 (41.8)	17 (41.5)	$\chi^2_2=0.131$	55 (39.3)	21 (50)	$\chi^2_2=3.843$
Student	52 (28.6)	41 (29.1)	11 (26.8)	$p=0.936$	45 (32.1)	7 (16.7)	$p=0.146$
Employed	25 (13.7)	41 (29.1)	13 (31.7)		40 (28.6)	14 (33.3)	
Family history, n (%)	25 (13.7)	22 (15.6)	3 (7.3)	$\chi^2_1=1.840$ $p=0.175$	17 (12.1)	8 (19.4)	$\chi^2_1=1.300$ $p=0.254$
Transition rate, n (%)	26 (14.3)	18 (12.8)	8 (19.5)	$\chi^2_1=1.181$ $p=0.277$	17 (12.1)	9 (21.4)	$\chi^2_1=2.275$ $p=0.131$

S.D., Standard deviation.

during the clinical follow-up period, as well as any incident use or changes to patterns of use.

In a minority of participants (n=41, 22.5%), it was not possible to complete all of the baseline substance use measures. The records for these individuals are missing some items relating to patterns of substance use, reasons for stopping cannabis use, or unpleasant experiences associated with cannabis use. Information on continued substance use was not available for 42 (23.1%) participants. The sample size available for each analysis thus varied depending on the completeness of the data for each measure. The missing information was due to non-attendance of appointments or disengagement from the clinical service. There were no statistically significant demographic or clinical differences between participants with complete and incomplete or missing data (Table 1).

Clinical follow-up

All 182 participants were followed up by OASIS for at least 2 years after presentation to determine whether or not transition to psychosis had occurred. Of the participants, 26 (14.3%) developed psychosis during this time.

Statistical analysis

Statistical analyses were performed using SPSS version 22 (IBM, USA). Two-tailed Pearson χ^2 and independent-samples t tests were used to investigate demographic and clinical differences according to completeness of record and substance use status. Two-tailed Pearson χ^2 tests and Kaplan–Meier survival analysis censored at 24 months from presentation to OASIS were used to explore differences in the rate of transition to psychosis in relation to baseline substance use and continued use during follow-up.

Ethics

Participants provided informed consent and the study was approved by the local research ethics committee.

Results

Substance use

At the time of the baseline assessment, 136 of the 182 participants (74.7%) had used an illicit substance on at least one occasion and 51 participants (28.0% of the total sample; 37.5% of substance users) were currently using an illicit substance. Use of two or more substances was reported by 78 participants (42.9% of the total sample; 57.4% of substance users). The prevalence and patterns of use for each type of substance are presented in Table 2.

Cannabis was the most commonly used substance, with 73.6% of the sample having tried it at least once.

Table 2. *Number of participants of the sample reporting lifetime, current, and frequent use for each substance/group of substances and the mean age of first and last use for users of each substance/group of substances*

Substance	Lifetime use Yes, n (%)	No, n	Current use Yes, n (%)	No, n	Frequent use Yes, n (%)	No, n	Mean age of first use, years (s.d.)	Mean age of last use, years (s.d.)
Cannabis	134 (73.6%)	48	36 (19.8%)	146	94 (52.2%)	86	15.5 (3.1)	21.3 (4.6)
Stimulants	62 (34.1%)	120	15 (8.3%)	166	26 (14.9%)	149	17.8 (3.4)	22.0 (5.6)
Cocaine	61 (33.5%)	121	17 (9.4%)	163	19 (11.1%)	153	18.1 (3.2)	21.7 (5.2)
Hallucinogens	42 (23.1%)	140	5 (2.8%)	176	9 (5.1%)	169	17.8 (3.2)	20.8 (5.0)
Inhalants	21 (11.5%)	161	2 (1.1%)	180	5 (2.8%)	173	14.7 (3.6)	16.4 (3.7)
Crack	16 (8.8%)	166	3 (1.7%)	179	7 (3.9%)	175	19.9 (4.9)	24.2 (5.8)
Opioids	12 (6.6%)	170	4 (2.1%)	177	7 (3.9%)	174	17.4 (2.4)	21.5 (7.2)
Sedatives	14 (7.7%)	168	5 (2.8%)	176	4 (2.2%)	175	19.6 (3.3)	23.7 (5.3)

s.d., Standard deviation.

Half reported using cannabis at a frequency of at least once per week (52.2%). About a quarter of lifetime cannabis users were currently using it at the time of presentation (26.9%). The mean duration of cannabis use was 6.0 years (s.d.=4.6, range 0–20) and long-term use (i.e. more than 5 years) was reported by 54 participants (30.7% of the sample).

Lifetime use of stimulants and cocaine was reported by about a third of the sample (34.1% and 33.5%, respectively). The rates of frequent use of these and other substances ranged between 2% and 15%. No more than 10% of the sample reported current use of substances other than cannabis.

Female participants were less likely to have tried cannabis than male participants (62.8% *v.* 79.8%, respectively; χ^2_1=6.455, p=0.011). No other differences in substance use were associated with demographic characteristics.

Adverse effects of cannabis use and reasons for cessation of use

Of the 155 lifetime cannabis users, 88 (76.5%) reported unpleasant experiences whilst using cannabis. Psychotic-like experiences (paranoia, hearing voices, having visions) were the most common, reported by 79 people (67.5%; see Fig. 1 for details of other adverse experiences). The majority of past cannabis users stopped because of unpleasant experiences (46 of 74 past users; 62.2%). Typical responses included: 'it made me more paranoid', 'I had panic attacks and paranoia – it sent me really weird' and 'it made my symptoms worse'. The remainder stopped because of a lack of positive effects ('it didn't do anything for me'; 'it stopped being enjoyable') or for practical or social reasons ('I didn't want to keep spending the money'; 'I moved away and changed my social situation ... left it behind').

Continued substance use during the follow-up period

Of the 140 participants whose substance use was re-assessed, 111 (79.3%) reported no change in their substance use: 37 non-users, 56 past users, and 18 current users remained as such. Twelve individuals who were current substance users at baseline had ceased their use during the follow-up period, while nine of the baseline past users subsequently resumed their substance use. Continued use of cannabis was reported by 31 individuals. Only eight (5.7%) participants started using a new substance after the baseline assessment: cannabis was tried by two people who had never used substances previously, while stimulants were tried by four individuals, cocaine by two, and hallucinogens by two, all of whom had previously used other substances.

Substance use and transition to psychosis

Table 3 shows the pattern of substance use in participants who did (n=26) and did not (n=156) develop psychosis during the follow-up period. There was no difference in transition rate between participants who had and had not tried cannabis prior to presentation (12.7% *v.* 18.8%, respectively, χ^2_1=1.061, p=0.303). Among lifetime users, there was a higher rate of transition to psychosis in those who had been frequent, as opposed to infrequent users [16 of 94 frequent users (17.0%) *v.* one of 38 infrequent users (2.6%); χ^2_1=4.994, p=0.025], and those whose first use was before the age of 15 years [12 of 56 early-onset users (21.4%) *v.* four of 71 late-onset users (5.6%); χ^2_1=7.093, p=0.008]. Moreover, early-onset users who then went

Fig. 1. Unpleasant experiences associated with cannabis use in ultra-high-risk participants (*n*=115). The chart shows the percentage of cannabis users who reported adverse effects.

Table 3. *Table showing the pattern of cannabis use in participants who did and did make a transition to psychosis*

|	Transition to psychosis		
	Yes, *n* (%)	No, *n* (%)	Transition rate, %
Lifetime use			
At least once, *n*	17 (65.4%)	117 (75%)	12.7%
Never, *n*	9 (34.6%)	39 (25%)	18.8%
Current use			
Current, *n*	8 (30.8%)	28 (17.9%)	22.2%
Past, *n*	9 (34.6%)	89 (57.1%)	9.2%
Never, *n*	9 (34.6%)	39 (25%)	18.8%
Frequent use			
Frequent, *n*	16 (61.5%)	78 (50.6%)	17%
Infrequent, *n*	1 (3.8%)	37 (24%)	2.6%
Never, *n*	9 (34.6%)	39 (25.3%)	18.8%
Early onset use			
Early onset, *n*	12 (48%)	44 (29.3%)	21.4%
Late onset, *n*	4 (16%)	67 (44.7%)	5.6%
Never, *n*	9 (36%)	39 (26%)	18.8%
Continued use during follow up			
Continued, *n*	6 (35.3%)	25 (20.3%)	19.4%
Discontinued, *n*	4 (23.5%)	66 (53.7%)	5.7%
Never, *n*	7 (41.2%)	32 (26%)	17.9%

on to use cannabis frequently had an even higher risk of transition than other cannabis users [12 of 48 early-onset frequent users (25%) *v.* four of 80 late-onset or infrequent users (5%); $\chi_1^2=10.971$, *p*=0.001]. Continued use of cannabis during the UHR follow-up period was also associated with an increased risk of transition to psychosis [six of 31 continued users (19.4%) *v.* four of 70 past users (5.7%); $\chi_1^2=4.481$, *p*=0.034]. However, in comparison to participants who had never tried the drug (transition rate 18.8%), the transition rates associated with frequent cannabis use, early-onset use, frequent use from early adolescence, and continued use were not significantly elevated ($\chi_1^2=0.065$, *p*=0.798; $\chi_1^2=0.115$, *p*=0.734; $\chi_1^2=0.549$, *p*=0.459; $\chi_1^2=0.023$, *p*=0.881, respectively). Fig. 2 shows the survival curves for non-users, infrequent or late-onset users, and frequent early-onset users of cannabis. Duration of total cannabis use did not influence the risk of later psychosis: nine of 54 long-term users made a transition to psychosis compared with seven of 74 short-term users (16.7% *v.* 9.5%, respectively; $\chi_1^2=1.483$, *p*=0.223). Lifetime cannabis use was not associated with an increased risk of transition to psychosis in participants who had a first-degree relative with psychosis: four of 14 people with a family history who also smoked cannabis developed psychosis (22.2%), compared with 13 of 116 cannabis users who did not have a family history (11.2%; $\chi_1^2=1.707$, *p*=0.191).

There were no statistically significant differences in the rate of transition to psychosis between lifetime users and non-users of any of the other substances assessed; similarly, current or frequent use of any substance was not associated with increased transition to psychosis (data not shown).

Discussion

In this study, we aimed to assess the influence of cannabis use on transition to psychosis in people at UHR of developing psychosis and to examine the extent to

Fig. 2. Survival curves for transition to psychosis over 2 years for early-onset frequent users, late-onset/infrequent users, and non-users of cannabis.

which this depends on age at first cannabis use, pattern of use, and genetic vulnerability for psychosis.

In general population samples, cannabis use in people experiencing psychosis-like phenomena but not seeking clinical help has been associated with a greater risk of later psychosis (Casadio *et al.* 2011). In our help-seeking UHR sample, we did not find lifetime cannabis use to be associated with transition to psychosis in the 24-month follow-up period. Although contrary to our primary hypothesis, this result is consistent with the data of Phillips *et al.* (2002) and Auther *et al.* (2012), who also found no association between lifetime cannabis use and subsequent onset of psychosis. However, among lifetime cannabis users in our sample, frequent cannabis use, early age of first use, and continued use over the UHR follow-up period were all associated with increased risk of transition to psychosis. These findings support our secondary hypotheses and are consistent with data from another study in UHR participants (Kristensen & Cadenhead, 2007) and studies of cannabis use in first-episode psychosis samples (Di Forti *et al.* 2009; Gonzalez-Pinto *et al.* 2011; Stone *et al.* 2014).

Participants who had used cannabis frequently from before the age of 15 years had a higher risk of developing psychosis than those who had become frequent users later in life or had only used cannabis infrequently. The apparent interaction between the age at first use and the frequency of use is consistent with previous studies showing that cannabis use increases the risk of psychosis when use begins in early adolescence (Arseneault *et al.* 2002). Both this finding and the lack of an association between long-term cannabis use and transition provide support for the hypothesis that it is exposure to cannabis during a sensitive period of neurodevelopment that increases the risk of psychosis, rather than cumulative exposure over the lifetime. Studies in humans and other animals show that exposure to cannabis has many effects on the brain (Batalla *et al.* 2013) and these effects appear to have the greatest potential for harm when exposure occurs during adolescence (Chadwick *et al.* 2013; Rubino & Parolaro, 2013). There are several possible mechanisms through which cannabis use during adolescence could increase the neurobiological predisposition to psychosis. It is thought that cannabis could act to disrupt normal neurodevelopment directly via the endocannabinoid system or indirectly through its actions on other neurotransmitter systems and brain regions involved in neurodevelopment. The endocannabinoid system in the brain is

known to play an important role in neurodevelopmental processes during adolescence and exogenous cannabinoids could disrupt these processes (Chadwick *et al.* 2013). Several brain regions are known to be rich in presynaptic cannabinoid receptors that modulate glutamatergic and GABAergic neurotransmission, so it is possible that over-exposure to cannabis could lead to neurotoxicity and reduced neuroplasticity (Hermann & Schneider, 2012; Rapp *et al.* 2012). For example, chronic cannabis use is associated with structural changes in the hippocampus, a brain area which undergoes considerable change during adolescence and is consistently found to be abnormal in psychosis (Rocchetti *et al.* 2013).

Despite the large evidence base showing a link between cannabis and psychosis, it is generally accepted that cannabis use alone is neither sufficient nor necessary to cause psychosis (Gage *et al.* 2013), and this view is consistent with our finding that lifetime users were no more likely to develop psychosis than those who had never used cannabis. It is likely that other unmeasured or unknown risk factors, in combination with underlying psychosis vulnerability, are responsible for the high rate of transition in the non-use group (van Nierop *et al.* 2013). The particularly low rates of transition associated with infrequent use (2.8%), cessation of use (9.4%) and later onset of use (5.6%), however, were unexpectedly low compared with UHR participants who had never used cannabis (18.8%). It is possible that, in the UHR group, these patterns of use might represent proxy markers for some potentially protective characteristics, such as good socio-occupational function (Rebgetz *et al.* 2013; Valmaggia *et al.* 2013).

Previous studies have suggested that cannabis use is more likely to be associated with psychotic symptoms when people have a family history of psychotic disorder (Miller *et al.* 2001; Stowkowy & Addington, 2013) and an investigation in UHR individuals provides further support for an interaction between cannabis use and genetic vulnerability in determining psychosis risk (Kristensen & Cadenhead, 2007). In our study, however, there was no significant effect of familial risk for psychosis on the rate of transition in cannabis users. It is possible that our study was underpowered to detect such an effect, as only a small proportion (14%) of UHR participants had a family history of psychosis. Future work in larger UHR samples could investigate the interaction between cannabis use and genes specifically implicated in mediating its effects on psychosis, such as AKT1 (van Winkel *et al.* 2010; Bhattacharyya *et al.* 2012*a*), as well as other known risk factors for psychosis, such as childhood adversity and urbanicity (van Nierop *et al.* 2013).

Almost three-quarters of the sample had tried cannabis and over half had used cannabis on a frequent basis. This rate of lifetime use is higher than that estimated for the general population of young adults in the UK (35%; European Monitoring Centre for Drugs and Drug Addiction, 2013), but comparable with that found in people with first-episode psychosis from the same geographical area (57–72%; Jonsson *et al.* 2004; Di Forti *et al.* 2009). However, the majority of cannabis users in this sample had stopped using cannabis long before they presented to OASIS; in contrast, among first-episode patients, most lifetime cannabis users were still using cannabis in the month prior to presentation (91%; Jonsson *et al.* 2004). The main reason for cessation of cannabis use in this study was adverse effects generated by the drug, particularly paranoia or exacerbation of existing attenuated psychotic symptoms. The discontinuation of cannabis use was self-initiated and not a result of clinical intervention, as it predated contact with OASIS and other health services. This suggests that it is unlikely that UHR participants were using cannabis as a form of self-medication for attenuated psychotic symptoms and is consistent with the mood-enhancing motivation for use described by Gill *et al.* (2013): if the effects of cannabis were becoming unpleasant and causing feelings of anxiety and depression, then it makes sense that people would stop using it. UHR individuals may also be more likely to link their psychotic experiences to cannabis use, and therefore stop using the drug: people at UHR differ from people with a psychotic disorder in being more likely to attribute psychotic phenomena to a problem with their health, as opposed to external agencies or supernatural forces (Lappin *et al.* 2007). These possibilities could have implications for clinical work with people at UHR of psychosis or public health campaigns regarding substance use in young people more generally. Continued exploration of the motivations for starting and stopping substance use and individual differences in how people experience the effects of cannabis use will therefore be useful.

Limitations

This study investigated associations between transition to psychosis and substance use assessed at two time points over 2 years in the largest sample of UHR individuals to date. Assessment of other outcomes such as social and occupational functioning and severity of psychotic symptoms would have allowed a richer exploration of the potential long-term effects of cannabis and other substance use in the UHR group. Moreover, inclusion of other potential confounding factors known to be related to cannabis use and psychosis, such as

childhood trauma, cognitive function, and use of tobacco, would have improved the study. The additional substance use assessment indicated relatively low rates of incident or resumed cannabis use, which is consistent with another study involving repeated measures in a similar high-risk sample that found no incident substance use among participants who were not already users at presentation (Corcoran *et al.* 2008). Nevertheless, regular assessment of substance use anchored to clinical assessments throughout the follow-up period would have allowed an opportunity to investigate the nature of the temporal relationship between cannabis use and the expression of psychotic symptoms and onset of psychosis in more detail. Our study also relied upon self-reported substance use. While the high rates of lifetime use reported suggest that participants were being truthful, there may have been an incentive to minimize or deny current or recent use, as the individuals were seeking help from a clinical service. Due to the low numbers of participants who used cannabis relatively infrequently, we used a dichotomous frequency variable, which applied only to the period of most regular use, as a measure of overall cannabis exposure. This measure was therefore unlikely to provide an accurate reflection of lifetime cumulative exposure to cannabis, and precluded further investigation of any dose–response relationship that might exist. No information was available regarding the type of cannabis that was used, which might be relevant to the risk of psychosis, as this is known to vary with the tetrahydrocannabinol (THC) content of cannabis (Di Forti *et al.* 2009). Consideration should also be given to the extent to which the current findings regarding cannabis use and the onset of psychosis can be generalized. UHR individuals who present to early-intervention teams may not be representative of all people at increased risk of developing psychosis, some of whom may be unwilling or unable to access mental health services.

Conclusion

When considering lifetime users of cannabis, the results of this study are broadly consistent with previous research showing an association between cannabis use and psychosis, in that frequent cannabis use, especially from an early age, and continued use in the context of attenuated psychotic symptoms were associated with transition to psychosis. Although the vast majority of the sample had tried cannabis at some point and over half had used it frequently, most UHR participants with a history of cannabis use did not develop a psychotic disorder and were no more likely to do so than those who had never tried it. Future work investigating cannabis use in the UHR group should seek to determine, through repeated assessment of substance use alongside other potential risk factors and multiple outcomes, the interplay between cannabis, pre-existing vulnerability for psychosis, and symptom expression in the onset of psychosis.

References

Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS (2013). Substance use in clinical high risk for psychosis: a review of the literature. *Early Intervention in Psychiatry*. Published online 14 November 2013. doi: 10.1111/eip.12100.

Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. *British Medical Journal* **325**, 1212–1213.

Auther AM, McLaughlin D, Carrion RE, Nagachandran P, Correll CU, Cornblatt BA (2012). Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. *Psychological Medicine* **42**, 2485–2497.

Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. *Psychopathology* **39**, 175–178.

Batalla A, Crippa JA, Busatto GF, Guimaraes FS, Zuardi AW, Valverde O, Atakan Z, McGuire PK, Bhattacharyya S, Martin-Santos R (2013). Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. *Current Pharmaceutical Design*. Published online 14 June 2013. doi: 10.2174/13816128113199990432.

Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D, Williams S, Brammer M, Collier DA, McGuire PK (2012*a*). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ−9-tetrahydrocannabinol on midbrain and striatal function. *Molecular Psychiatry* **17**, 1152–1155.

Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, O'Carroll C, Seal ML, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire PK (2012*b*). Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. *Archives of General Psychiatry* **69**, 27–36.

Casadio P, Fernandes C, Murray RM, Di Forti M (2011). Cannabis use in young people: the risk for schizophrenia. *Neuroscience and Biobehavioural Reviews* **35**, 1779–1787.

Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-*O*-methyltransferase gene: longitudinal evidence of a gene x environment interaction. *Biological Psychiatry* **57**, 1117–1127.

Chadwick B, Miller ML, Hurd YL (2013). Cannabis use during adolescent development: susceptibility to psychiatric illness. *Frontiers in Psychiatry* **4**, 129.

Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, Schobel S, Harkavy-Friedman J, Goetz R, Colibazzi T, Cressman V, Malaspina D (2008). Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. *Schizophrenia Research* **106**, 286–293.

Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. *Biological Psychiatry* **72**, 811–816.

Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM (2009). High-potency cannabis and the risk of psychosis. *British Journal of Psychiatry* **195**, 488–491.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2013). *National Report 2012: United Kingdom.* EMCDDA: Lisbon.

Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia LR, Barale F, Caverzasi E, McGuire PK (2012). Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Archives of General Psychiatry* **69**, 220–229.

Gage SH, Zammit S, Hickman M (2013). Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. *F1000 Medicine Reports* **5**, 2.

Gill KE, Poe L, Azimov N, Ben-David S, Vadhan NP, Girgis R, Moore H, Cressman V, Corcoran CM (2013). Reasons for cannabis use among youths at ultra high risk for psychosis. *Early Intervention in Psychiatry.* Published online 26 November 2013. doi: 10.1111/eip.12112.

Gonzalez-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibanez B, Haidar MK, Vieta E, Arango C (2011). Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. *Schizophrenia Bulletin* **37**, 631–639.

Grech A, van Os J, Jones PB, Lewis SW, Murray RM (2005). Cannabis use and outcome of recent onset psychosis. *European Psychiatry* **20**, 349–353.

Hall W, Degenhardt L (2000). Cannabis use and psychosis: a review of clinical and epidemiological evidence. *Australian and New Zealand Journal of Psychiatry* **34**, 26–34.

Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen H-U, van Os J (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. *BMJ* **330**, 11.

Hermann D, Schneider M (2012). Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. *Current Pharmaceutical Design* **18**, 4897–4905.

Jonsson F, Freeman J, Hinton M, Towle L, O'Donnell J, Power P (2004). Cannabis and psychosis: a clinical audit of the prevalence and persistence of cannabis use in first-episode psychosis patients attending the Lambeth Early Onset (LEO) service in London. *Schizophrenia Research* **70** (Suppl. 1), 72.

Konings M, Henquet C, Maharajh HD, Hutchinson G, van Os J (2008). Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. *Acta Psychiatrica Scandinavica* **118**, 209–213.

Kristensen K, Cadenhead KS (2007). Cannabis abuse and risk for psychosis in a prodromal sample. *Psychiatry Research* **151**, 151–154.

Lappin JM, Morgan KD, Valmaggia LR, Broome MR, Woolley JB, Johns LC, Tabraham P, Bramon E, McGuire PK (2007). Insight in individuals with an at risk mental state. *Schizophrenia Research* **90**, 238–244.

Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. *Lancet* **363**, 1579–1588.

Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC (2001). Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh Study of People at High Risk for Schizophrenia. *Social Psychiatry and Psychiatric Epidemiology* **36**, 338–342.

Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet* **370**, 319–328.

Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD (2002). Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. *Australian and New Zealand Journal of Psychiatry* **36**, 800–806.

Rapp C, Bugra H, Riecher-Rossler A, Tamagni C, Borgwardt S (2012). Effects of cannabis use on human brain structure in psychosis: a systematic review combining *in vivo* structural neuroimaging and post mortem studies. *Current Pharmaceutical Design* **18**, 5070–5080.

Rebgetz S, Conus P, Hides L, Kavanagh DJ, Cotton S, Schimmelmann BG, McGorry PD, Lambert M (2013). Predictors of substance use reduction in an epidemiological first-episode psychosis cohort. *Early Intervention in Psychiatry.* Published online 24 July 2013. doi: 10.1111/eip.12067.

Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, Fusar-Poli P (2013). Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. *Psychiatry and Clinical Neurosciences* **67**, 483–492.

Rubino T, Parolaro D (2013). Cannabis abuse in adolescence and the risk of psychosis: a brief review of the preclinical evidence. *Progress in Neuropsychopharmacology and Biological Psychiatry*. Published online 31 July 2013. doi: 10.1016/j.pnpbp.2013.07.020.

Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA (2013). Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. *Schizophrenia Bulletin* **39**, 251–254.

Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, Rahaman N, Joyce J, Hinton M, Johnson S, Young AH (2014). Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. *Psychological Medicine* **44**, 499–506.

Stowkowy J, Addington J (2013). Predictors of a clinical high risk status among individuals with a family history of psychosis. *Schizophrenia Research* **147**, 281–286.

Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, Bertani M, Bissoli S, Lazzarotto L, Marrella G, Lamonaca D, Riolo R, Gardellin F, Urbani A, Tansella M, Ruggeri M; PICOS-VENETO Group (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). *Journal of Psychiatric Research* **47**, 438–444.

United Nations Office on Drugs and Crime (2013). *World Drug Report 2013*. UNODC: Vienna (http://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf).

Valmaggia LR, Stahl D, Yung AR, Nelson B, Fusar-Poli P, McGorry PD, McGuire PK (2013). Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. *Psychological Medicine* **43**, 2311–2325.

van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L (2012). Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. *Current Pharmaceutical Design* **18**, 5036–5044.

van Nierop M, Janssens M; Genetic Risk and Outcome of Psychosis (GROUP) Investigators, Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D (2013). Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. *PLOS ONE* **8**, e76690.

van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002). Cannabis use and psychosis: a longitudinal population-based study. *American Journal of Epidemiology* **156**, 319–327.

van Winkel R, Esquivel G, Kenis G, Wichers M, Collip D, Peerbooms O, Rutten B, Myin-Germeys I, van Os J (2010). Review: genome-wide findings in schizophrenia and the role of gene–environment interplay. *CNS Neuroscience and Therapeutics* **16**, 185–192.

van Winkel R; Genetic Risk and OUtcome of Psychosis (GROUP) Investigators (2011). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. *Archives of General Psychiatry* **68**, 148–157.

Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, Patton GC, Jackson HJ (1998). Prediction of psychosis. A step towards indicated prevention of schizophrenia. *British Journal of Psychiatry Supplement* **172**, 14–20.